Narrator: This is Science Today. Cancer researchers at the University of California, San Francisco, have found encouraging results treating patients with advanced colorectal cancer using low doses of an antibody of a protein called vascular endothelial cell growth factor, or VEGF, along with chemotherapy. But Dr. Emily Bergsland says their results are preliminary and that researchers still have a lot to learn about the biology of VEGF.
Bergsland: We need to learn more about the safety and also its efficacy. We need to look at it in larger groups of patients before this becomes a regular part of our practice in oncology.
Narrator: Their results suggested there might be increased activity in tumor shrinkage when chemotherapy is combined with a VEGF antibody.
Bergsland: I think it represents a step in the right direction. We're moving towards understanding how cancer develops and how tumors grow and metastasize and ultimately, hopefully, we can tailor therapy based on an individual patient's tumor type. And that is the long-term goal.
Narrator: For Science Today, I'm Larissa Branin.